- Home
- CHRS vs PROV Comparison
CHRS vs PROV Comparison
Compare CHRS & PROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PROV
- Stock Information
- Founded
- CHRS 2010
- PROV 1956
- Country
- CHRS United States
- PROV United States
- Employees
- CHRS N/A
- PROV N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PROV Savings Institutions
- Sector
- CHRS Health Care
- PROV Finance
- Exchange
- CHRS Nasdaq
- PROV Nasdaq
- Market Cap
- CHRS 102.0M
- PROV 100.7M
- IPO Year
- CHRS 2014
- PROV 1996
- Fundamental
- Price
- CHRS $1.05
- PROV $15.30
- Analyst Decision
- CHRS Buy
- PROV Hold
- Analyst Count
- CHRS 3
- PROV 1
- Target Price
- CHRS $4.68
- PROV $16.50
- AVG Volume (30 Days)
- CHRS 1.5M
- PROV 5.0K
- Earning Date
- CHRS 08-07-2025
- PROV 07-28-2025
- Dividend Yield
- CHRS N/A
- PROV 3.66%
- EPS Growth
- CHRS N/A
- PROV N/A
- EPS
- CHRS 1.55
- PROV 0.93
- Revenue
- CHRS $272,209,000.00
- PROV $39,666,000.00
- Revenue This Year
- CHRS N/A
- PROV $10.39
- Revenue Next Year
- CHRS $142.61
- PROV N/A
- P/E Ratio
- CHRS $2.05
- PROV $16.45
- Revenue Growth
- CHRS 52.33
- PROV 1.90
- 52 Week Low
- CHRS $0.66
- PROV $12.91
- 52 Week High
- CHRS $2.43
- PROV $16.70
- Technical
- Relative Strength Index (RSI)
- CHRS 62.88
- PROV 46.10
- Support Level
- CHRS $0.81
- PROV $15.02
- Resistance Level
- CHRS $0.95
- PROV $15.60
- Average True Range (ATR)
- CHRS 0.07
- PROV 0.21
- MACD
- CHRS 0.01
- PROV 0.01
- Stochastic Oscillator
- CHRS 85.71
- PROV 50.16
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.